부산대학교 도서관

The presence of type 2 diabetes has traditionally been associated with increased cardiovascular risk. However, this risk is heterogeneous: the latest European guidelines, stratify patients according to risk categories, and provide advice accordingly. The results of cardiovascular outcome trials in diabetes have impacted these recommendations. Meta-analysis results clearly show that both SGLT2 inhibitors and GLP-1 receptor agonists show positive results in secondary prevention patients. The evidence for MACE in primary prevention (patients with multiple risk factors) is based only on subgroup analyses. However, both classes have shown benefit in hospitalization for heart failure and renal outcomes, independent of primary or secondary prevention. In addition, these benefits appear to be independent of baseline HbA1c. We now have a better understanding of the cardiovascular risk continuum in diabetes. Comprehensive treatment strategies should be implemented that are effective in reducing events the risk continuum.